Active compounds-based discoveries about the differentiation and apoptosis of leukemic cells

Chinese Science Bulletin

Volumn 54, Issue 22, 2009, Pages 4094-4101

  Chen, GuoQiang ^a,b   Zhang, Jing ^b   Zhao, Qian ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b Chinese Academy of Sciences   (China)

Author keywords

Apoptosis; Cell differentiation; Chemical biology; Leukemia

Indexed keywords

EID: 74549179661     PISSN: 10016538     EISSN: 18619541     Source Type: Journal    
DOI: 10.1007/s11434-009-0628-y     Document Type: Review

References (65)

1. Chen G Q, Wang L S, Wu Y L, et al. Leukemia, an effective model for chemical biology and target therapy. Acta Pharmacol Sin, 2007, 28: 1316-1324.
2. Huang M E, Ye Y C, Chen S R, et al. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. Chin Med J, 1987, 100: 949-953.
3. Huang M E, Ye Y C, Chen S R, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 1988, 72: 567-572.
4. Collins S J. Retinoic acid receptors, hematopoiesis and leukemogenesis. Curr Opin Hematol, 2008, 15: 346-351.
5. Drumea K, Yang Z F, Rosmarin A. Retinoic acid signaling in myelopoiesis. Curr Opin Hematol, 2008, 15: 37-41.
6. Tsiftsoglou A S, Pappas I S, Vizirianakis I S. Mechanisms involved in the induced differentiation of leukemia cells. Pharmacol Ther, 2003, 100: 257-290.
7. Zhu J, Shi X G, Chu H Y, et al. Effect of retinoic acid isomers on proliferation, differentiation and PML relocalization in the APL cell line NB4. Leukemia, 1995, 9: 302-309.
8. Mao M, Yu M, Tong J H, et al. RIG-E, a human homolog of the murine Ly-6 family, is induced by retinoic acid during the differentiation of acute promyelocytic leukemia cell. Proc Natl Acad Sci USA, 1996, 93: 5910-5914.
9. Liu T X, Zhang J W, Tao J, et al. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood, 2000, 96: 1496-1504.
10. Huang S, Shen Q, Mao W G, et al. JWA, a novel signaling molecule, involved in the induction of differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun, 2006, 341: 440-450.
11. Wang J, Fong C C, Tzang C H, et al. Gene expression analysis of human promyelocytic leukemia HL-60 cell differentiation and cytotoxicity induced by natural and synthetic retinoids. Life Sci, 2009, 84: 576-583.
12. Zhao Q, Tao J, Zhu Q, et al. Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation. Leukemia, 2004, 18: 285-292.
13. Chen S, Han Y H, Zheng Y, et al. NDRG1 contributes to retinoic acid-induced differentiation of leukemic cells. Leuk Res, 2009, 33: 1108-1113.
14. Liu J, Bi G, Wen P, et al. Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol, 2007, 4: 59-63.
15. Zhou Q, Zhao J, Stout J G, et al. Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids. J Biol Chem, 1997, 272: 18240-18244.
16. Zhao K W, Li X, Zhao Q, et al. Protein kinase Cdelta mediates retinoic acid and phorbol myristate acetate-induced phospholipid scramblase 1 gene expression: Its role in leukemic cell differentiation. Blood, 2004, 104: 3731-3738.
17. Radominska-Pandya A, Chen G, Czernik P J, et al. Direct interaction of all-trans-retinoic acid with protein kinase C (PKC). Implications for PKC signaling and cancer therapy. J Biol Chem, 2000, 275: 22324-22330.
18. Zhou Q, Zhao J, Al-Zoghaibi F, et, al. Transcriptional control of the human plasma membrane phospholipid scramblase 1 gene is mediated by interferon-alpha. Blood, 2000, 95: 2593-2599.
19. Zhao K W, Li D, Zhao Q, et al. Interferon-alpha-induced expression of phospholipid scramblase 1 through STAT1 requires the sequential activation of protein kinase Cdelta and JNK. J Biol Chem, 2005, 280: 42707-42714.
20. Huang Y, Zhao Q, Zhou C X, et al. Antileukemic roles of human phospholipid scramblase 1 gene, evidence from inducible PLSCR1-expressing leukemic cells. Oncogene, 2006, 25: 6618-6627.
21. Zhang K, Guo Q L, You Q D, et al. Wogonin induces the granulocytic differentiation of human NB4 promyelocytic leukemia cells and up-regulates phospholipid scramblase 1 gene expression. Cancer Sci, 2008, 99: 689-695.
22. Sun H D, Ma L. Treatment of 32 acute promyelocytic leukemia (APL) patients with combination of AiLing I and Chinese medicine. Chin J Integrat Med, 1992, 3: 170-171.
23. Zhang P, Wang S Y, Hu L H, et al. Use of arsenic trioxide (As2O3) injection in the treatment of 72 acute promyelocytic leukemia (APL) patients. Chin J Hematol, 1996, 2: 58-60.
24. Shen Z X, Chen G Q, Ni J H, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 1997, 89: 3354-3360.
25. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood, 1999, 94: 3315-3324.
26. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood, 1996, 88: 1052-1061.
27. Chen G Q, Zhou L, Styblo M, et al. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res, 2003, 63: 1853-1859.
28. Chen Z, Chen G Q, Shen Z X, et al. Expanding the use of arsenic trioxide: Leukemias and beyond. Semin Hematol, 2002, 39(2 Suppl 1): 22-26.
29. Zhu X H, Shen Y L, Jing Y K, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst, 1999, 91: 772-778.
30. Cai X, Yu Y, Huang Y, et al. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia, 2003, 17: 1333-1337.
31. Cai X, Shen Y L, Zhu Q, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia, 2000, 14: 262-270.
32. Yan H, Wang Y C, Li D, et al. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: The role of protein kinase Cdelta. Leukemia, 2007, 21: 1488-1495.
33. 3 exerts dose-dependent dual effects on APL cells. Blood, 1997, 89: 3345-3353.
34. Huang Y, Du K M, Xue Z H, et al. Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1alpha. Leukemia, 2003, 17: 2065-2073.
35. Liu W, Guo M, Xu Y B, et al. Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia. Blood, 2006, 107: 698-707.
36. Han Y H, Xia L, Song L P, et al. Comparative proteomic analysis of hypoxia-treated and untreated human leukemic U937 cells. Proteomics, 2006, 6: 3262-3274.
37. Liao S H, Zhao X Y, Han Y H, et al. Proteomics-based identification of two novel direct targets of hypoxia-inducible factor-1a and their potential roles in migration/invasion of cancer cells. Proteomics, 2009, 15: 3901-3912.
38. Jiang Y, Xue Z H, Shen W Z, et al. Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha. Leukemia, 2005, 19: 1239-1247.
39. Xue Z H, Jiang Y, Yu Y, et al. Metavanadate suppresses desferrioxamine-induced leukemic cell differentiation with reduced hypoxia-inducible factor-1alpha protein. Biochem Biophys Res Commun, 2005, 332: 1140-1145.
40. Song L P, Zhang J, Wu S F, et al. Hypoxia-inducible factor-1alpha-induced differentiation of myeloid leukemic cells is its transcriptional activity independent. Oncogene, 2008, 27: 519-527.
41. Xu M, Li D, Lu Y, et al. Leukemogenic AML1-ETO fusion protein increases carcinogen-DNA adduct formation with upregulated expression of cytochrome P450-1A1 gene. Exp Hematol, 2007, 35: 1249-1255.
42. Gao F H, Wang Q, Wu Y L, et al. c-Jun N-terminal kinase mediates AML1-ETO protein-induced connexin-43 expression. Biochem Biophys Res Commun, 2007, 356: 505-511.
43. Li X, Xu Y B, Wang Q, et al. Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: The role in AML 1-ETO-induced growth arrest in leukemic cells. J Cell Physiol, 2006, 208: 594-601.
44. Zhang L, Wang L S, Xu Y, et al. Comparative proteomic analysis of human leukemic cells with and without inducible expression of leukemogenic AML1-ETO protein. Chin J Physiol, 2006, 49: 182-191.
45. Peng Z G, Zhou M Y, Huang Y, et al. Physical and functional interaction of Runt-related protein 1 with hypoxia-inducible factor1alpha. Oncogene, 2008, 27: 839-847.
46. Yang L, Jiang Y, Wu S F, et al. CCAAT/enhancer-binding protein alpha antagonizes transcriptional activity of hypoxia-inducible factor 1 alpha with direct protein-protein interaction. Carcinogenesis, 2008, 29: 291-298.
47. Yan H, Peng Z G, Wu Y L, et al. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells. Haematologica, 2005, 90: 1607-1616.
48. Zhang J, Song L P, Huang Y, et al. Accumulation of hypoxia-inducible factor-1 alpha protein and its role in the differentiation of myeloid leukemic cells induced by all-trans retinoic acid. Haematologica, 2008, 93: 1480-1487.
49. Janardhan H P. The HIF-1 alpha-C/EBP alpha axis. Sci Signal, 2008, 1(43): jc2.
50. Zhang J, Chen G Q. Hypoxia-HIF-1alpha-C/EBPalpha/Runx1 signaling in leukemic cell differentiation. Pathophysiology, 2009, doi: 10. 1016/j. pathophys. 2009. 02. 005.
51. Kim J S, Cho E W, Chung H W, et al. Effects of Tiron, 4, 5-dihydroxy-1, 3-benzene disulfonic acid, on human promyelotic HL-60 leukemia cell differentiation and death. Toxicology, 2006, 223: 36-45.
52. Song M G, Gao S M, Du K M, et al. Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cdelta-dependent mechanisms. Blood, 2005, 105: 3714-3721.
53. Liu W, Zhu Y S, Guo M, et al. Therapeutic efficacy of NSC606985, a novel camptothecin analog, in a mouse model of acute promyelocytic leukemia. Leuk Res, 2007, 31: 1565-1574.
54. Tan C, Cai L Q, Wu W, et al. NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells. Cancer Chemother Pharmacol, 2009, 63: 303-312.
55. Zhang N, Zhang H, Xia L, et al. NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF-1alpha protein in human ovarian cancer cells. Cancer Lett, 2009, 278: 139-144.
56. Zheng Y, Wang L S, Xia L, et al. NDRG1 is down-regulated in the early apoptotic event induced by camptothecin analogs: the potential role in proteolytic activation of PKC delta and apoptosis. Proteomics, 2009, 9: 2064-2075.
57. Yu Y, Wang L S, Shen S M, et al. Subcellular proteome analysis of camptothecin analogue NSC606985-treated acute myeloid leukemic cells. J Proteome Res, 2007, 6: 3808-3818.
58. Wang S, Zheng Y, Yu Y, et al. Phosphorylation of beta-actin by protein kinase C-delta in camptothecin analog-induced leukemic cell apoptosis. Acta Pharmacol Sin, 2008, 29: 135-142.
59. Yuan T T, Huang Y, Zhou C X, et al. Nuclear translocation of dihydrofolate reductase is not a pre-requisite for DNA damage induced apoptosis. Apoptosis, 2009, 14: 699-710.
60. Zhao M, Duan X F, Wen D H, et al. PU. 1, a novel caspase-3 substrate, partially contributes to chemotherapeutic agents-induced apoptosis in leukemic cells. Biochem Biophys Res Commun, 2009, 382: 508-513.
61. Lu Y, Peng Z G, Yuan T T, et al. Multi-sites cleavage of leukemogenic AML1-ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivity. Leukemia, 2008, 22: 378-386.
62. Lu Y, Xu Y B, Yuan T T, et al. Inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis. Leukemia, 2006, 20: 987-993.
63. Zhao Y, Pu J X, Huang S X, et al. ent-Kaurane diterpenoids from Isodon pharicus. J Nat Prod, 2009, 72: 988-993.
64. Zhao Y, Pu J X, Huang S X, et al. ent-Kaurane diterpenoids from Isodon scoparius. J Nat Prod, 2009, 72: 125-129.
65. Zhou G B, Kang H, Wang L, et al. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8; 21) leukemia in vitro and in vivo. Blood, 2007, 109: 3441-3450.